Patnaik, Amita http://orcid.org/0000-0002-4144-2193
Weiss, Glen J.
Rasco, Drew W.
Blaydorn, Lisa
Mirabella, Amy
Beeram, Murali
Guo, Wei
Lu, Sharon
Danaee, Hadi
McEachern, Kristen
Im, Ellie
Sachdev, Jasgit C.
Clinical trials referenced in this document:
Documents that mention this clinical trial
83 Time course of adverse events during dostarlimab treatment in patients with recurrent or advanced endometrial cancer in the garnet trial
https://doi.org/10.1136/ijgc-2021-esgo.113
2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial
https://doi.org/10.1136/ijgc-2022-esgo.878
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
https://doi.org/10.1136/ijgc-2022-004178
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
https://doi.org/10.1007/s00280-021-04358-3
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study (Pre-results)
https://doi.org/10.1136/jitc-2021-003777
386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
https://doi.org/10.1136/ijgc-2020-esgo.72
EP134/#1505 Dostarlimab monotherapy in mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer in the Korean expanded access program
https://doi.org/10.1136/ijgc-2023-igcs.230
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
https://doi.org/10.1136/ijgc-2022-003492
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study
https://doi.org/10.1136/ijgc-2020-esgo.71
Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk
https://doi.org/10.1136/bmjopen-2021-060423
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Funding for this research was provided by:
glaxosmithkline
Article History
Received: 23 June 2021
Accepted: 22 September 2021
First Online: 8 November 2021
Declarations
:
: Dr. Patnaik reports institutional grants from GlaxoSmithKline. Dr. Weiss is an employee of SOTIO, LCC, outside of this submitted work, and a former employee of Unum Therapeutics outside of this submitted work; he reports personal fees from Spring Bank Pharmaceuticals, Imaging Endpoints II, MiRanostics Consulting, Gossamer Bio, Paradigm, International Genomics Consortium, Angiex, IBEX Medical Analytics, GLG Council, Guidepoint Global, Circulogene, and Genomic Health, all outside this submitted work; he has received travel reimbursement from Cambridge Healthtech Institute, GlaxoSmithKline, and Tesaro; has ownership interest in MiRanostics Consulting, Unum Therapeutics (now Cogent Biosciences), Exact Sciences, Moderna, and Circulogene, all outside the submitted work; and has issued patents PCT/US2008/072787, PCT/US2010/043777, PCT/US2011/020612, and PCT/US20211037616, all outside this submitted work. Dr. Rasco reports institutional grants from GlaxoSmithKline. Dr. Blaydorn has nothing to disclose. Dr. Mirabella has nothing to disclose. Dr. Beeram has nothing to disclose. Dr. Guo, Dr. Lu, Dr. Danaee, and Dr. Im are all former employees of GlaxoSmithKline. Dr. McEachern is a former GlaxoSmithKline employee. Dr. Sachdev reports advisory roles at Celgene, PUMA, TTC Oncology, Pfizer, Novartis, TapImmune, Ipsen, Tempus, and AstraZeneca; honoraria from Ipsen, Celgene, PUMA, Novartis, Pfizer, Tempus, and AstraZeneca; and institutional grants from Pfizer, Celgene, and Genentech.
: The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
: The study was approved by the institutional review board at each participating site. All patients gave written informed consent to participate before enrollment.
: Not applicable.